| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ELMS STEVE | Director | C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK | /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact | 09 Mar 2026 | 0001250195 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADMA | Common Stock | Purchase | $109,690 | +7,000 | +0.34% | $15.67 | 2,038,730 | 05 Mar 2026 | See footnote | F1, F2, F3 |
| transaction | ADMA | Common Stock | Purchase | $107,730 | +7,000 | +0.34% | $15.39 | 2,045,730 | 06 Mar 2026 | See footnote | F2, F3, F4 |
| holding | ADMA | Common Stock | 98,020 | 05 Mar 2026 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive. |
| F2 | The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4. |
| F3 | Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein. |
| F4 | The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive. |
| F5 | Includes, as of the transaction date, (i) 10,690 restricted stock units granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 87,330 shares of common stock owned by the Reporting Person. |